AgomAb Therapeutics NV - ADRs representing one common share

Positive marks for focusing capital on organ‑restricted TGF‑β programs with promising early data, timing the IPO to extend runway into 1H29, and pursuing regulatory alignment ahead of a large Phase 2b. The company is exploring strategic options for AGMB‑101 rather than reflexively advancing all programs, which signals discipline.

Risks include the inherent dilution path of clinical biotechs if timelines extend or trials expand, and concentration in one biology (ALK5) across two indications.